Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study
Open Access
- 8 March 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 9 (2) , 194-201
Abstract
Background: MMR II (M-M-R II [Merck & Co, Inc.]) is currently the only measles, mumps, and rubella (MMR) vaccine licensed in the United States. A second MMR vaccine would mitigate the potential risk of vaccine supply shortage or delay. In this study, we assessed the immunogenicity and safety of another MMR vaccine (MMR-RIT [Priorix, GlaxoSmithKline]) compared with those of the MMR II in 12- to 15-month-old children who received it as a first dose.Methods: In this phase III, observer-blinded, noninferiority, lot-to-lot consistency clinical trial (ClinicalTrials.gov identifier NCT01702428), 5003 healthy children were randomly assigned to receive 1 dose of MMR-RIT (1 of 3 production lots) or MMR II along with other age-recommended routine vaccines. We evaluated the immunogenicity of all vaccines in terms of antibody concentrations (by using an enzyme-linked immunosorbent assay or electrochemiluminescence assay) and/or seroresponse rates 43 days after vaccination. We also assessed the reactogenicity and safety of the vaccines.Results: Immunoresponses after vaccination with MMR-RIT were robust and noninferior to those after vaccination with the MMR II. Immunogenicity of the 3 production lots of MMR-RIT was consistent; more than 97% of the children had a seroresponse to MMR components. The coadministered vaccines elicited similar immunoresponses in the MMR-RIT and MMR II groups. Both MMR vaccines resulted in comparable reactogenicity profiles, and no safety concerns were detected.Conclusions: If licensed, the MMR-RIT could provide a valid option for the prevention of measles, mumps, and rubella in children in the United States and would reduce potential risks of a vaccine shortage.Keywords
Funding Information
- GlaxoSmithKline
This publication has 15 references indexed in Scilit:
- Safety of Measles-Containing Vaccines in 1-Year-Old ChildrenPediatrics, 2015
- Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 MonthsJournal of the Pediatric Infectious Diseases Society, 2014
- Effect of Age on the Risk of Fever and Seizures Following Immunization With Measles-Containing Vaccines in ChildrenJAMA Pediatrics, 2013
- Immunogenicity and Safety of Two Tetravalent (Measles, Mumps, Rubella, Varicella) Vaccines Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children Twelve to Fourteen Months of AgeThe Pediatric Infectious Disease Journal, 2012
- Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile SeizuresPediatrics, 2010
- Measles, Mumps, Rubella Vaccine (Priorix???; GSK-MMR)Drugs, 2003
- Sequence Diversity of Jeryl Lynn Strain of Mumps Virus: Quantitative Mutant Analysis for Vaccine Quality ControlVirology, 2002
- A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed childrenInternational Journal of Infectious Diseases, 2002
- Comparison of Predicted Amino Acid Sequences of Measles Virus Strains in the Edmonston Vaccine LineageJournal of Virology, 2001
- Analysis of the Noncoding Regions of Measles Virus Strains in the Edmonston Vaccine LineageJournal of Virology, 2001